A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults With Major Depressive Disorder With Anxiety Symptoms

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults With Major Depressive Disorder With Anxiety Symptoms

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs ADX 71149 (Primary)
  • Indications Generalised anxiety disorder; Major depressive disorder; Panic disorder; Social phobia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 07 Feb 2014 According to an Addex Therapeutics media release, this study will be presented at a future scientific meeting and submitted for publication in a peer-reviewed medical journal.
    • 28 Jan 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top